Prescription Digital Therapy Now A Reality

The pursuit of offering ‘prescription digital therapeutics’ or ‘digiceuticals’ by Big Pharma, to ensure better clinical outcomes for patients, has apparently come to fruition now. On April 18, 2018, by a media release, Novartis announced that the Sandoz Division of the Company … Continue reading

Define And Adapt To Reality: Two Pivotal Pharma Leadership Skills For Sustainable Excellence

Max DePree – a much quoted American businessman and author had once said: “The first responsibility of a leader is to define reality.” While defining the reality within the drug industry today, it makes many industry leaders to ponder, despite … Continue reading

Access to Medicine: Losing Track in Cacophony

Indian Healthcare space is by and large an arena, where perceptions prevail over the changing reality in many important areas. Consequently, fierce discourse in those areas mostly gives rise to a cacophony of ‘Your Perceptions Against Mine’. It is intriguing, why even … Continue reading

‘Disease Oriented Treatment’ to ‘Patient Oriented Treatment’ – An evolving trend

The quest for moving away from conventional and error-prone ‘Disease Oriented Treatment’ paving the way for unconventional individual patient-specific ones, may soon come to fruition. Dramatic progress in the research for developing ‘Personalized Medicines’ could soon offer a choice for … Continue reading

Regulatory Data Protection (RDP) and its need in India: The Myth versus Reality

THE MYTH: An attempt to delay the launch of Indian generics: Some in India feel that Regulatory Data Protection (RDP), is a deliberate attempt by the innovator companies to delay the launch of the generic equivalent of patented products in … Continue reading

Regulatory Data Protection (RDP) and its need in India: The Myth versus Reality

THE MYTH: An attempt to delay the launch of Indian generics: Some in India feel that Regulatory Data Protection (RDP), is a deliberate attempt by the innovator companies to delay the launch of the generic equivalent of patented products in … Continue reading